EASTMAN CHEMICAL CO — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that EASTMAN CHEMICAL CO filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.75B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.38B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $9.21B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $10.58B | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | $2.69B | Feb 25, 2022 |
| FY2021 | Sep 30, 2021 | $2.72B | Feb 25, 2022 |
| FY2021 | Jun 30, 2021 | $2.65B | Feb 25, 2022 |
| FY2021 | Mar 31, 2021 | $2.41B | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $2.19B | Feb 25, 2022 |
| FY2021 | Sep 30, 2020 | $2.12B | Feb 25, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.84B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.29B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.06B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.14B | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | $559.00M | Feb 25, 2022 |
| FY2021 | Sep 30, 2021 | $662.00M | Feb 25, 2022 |
| FY2021 | Jun 30, 2021 | $681.00M | Feb 25, 2022 |
| FY2021 | Mar 31, 2021 | $598.00M | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $526.00M | Feb 25, 2022 |
| FY2021 | Sep 30, 2020 | $501.00M | Feb 25, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $474.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $905.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $894.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $793.00M | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | $378.00M | Feb 25, 2022 |
| FY2021 | Sep 30, 2021 | $351.00M | Feb 25, 2022 |
| FY2021 | Jun 30, 2021 | ($146.00M) | Feb 25, 2022 |
| FY2021 | Mar 31, 2021 | $274.00M | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | $32.00M | Feb 25, 2022 |
| FY2021 | Sep 30, 2020 | $161.00M | Feb 25, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.53B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $1.38B | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $1.38B | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $1.16B | Feb 27, 2017 |
| FY2015 | Dec 31, 2013 | $1.86B | Feb 25, 2016 |
| FY2014 | Dec 31, 2012 | $800.00M | Feb 27, 2015 |
| FY2013 | Dec 31, 2011 | $937.00M | Feb 28, 2014 |
| FY2012 | Dec 31, 2010 | $844.00M | Feb 28, 2013 |
| FY2011 | Dec 31, 2009 | $345.00M | Feb 22, 2012 |
| FY2010 | Dec 31, 2008 | $551.00M | Feb 23, 2011 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $250.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $239.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $264.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $254.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $226.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $234.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $235.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $227.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $223.00M | Feb 27, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $658.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $736.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $727.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $726.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $795.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $654.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $691.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $721.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $729.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $707.00M | Feb 27, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $970.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.29B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.37B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $975.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.62B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $1.46B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $1.50B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.54B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.66B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $1.39B | Feb 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $546.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $599.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $828.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $611.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $555.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $383.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $425.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $528.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $649.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $626.00M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.86B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $15.21B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $14.63B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $14.67B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $15.52B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $16.08B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $16.01B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $16.00B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $16.00B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $15.46B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.82B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $9.36B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $9.10B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $9.43B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $9.73B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $9.98B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $9.98B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $10.12B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $10.52B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $10.85B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.96B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.78B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $5.46B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $5.15B | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $5.70B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $6.02B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $5.96B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.80B | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $5.40B | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $4.53B | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.67B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.63B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.65B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.66B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.64B | Feb 14, 2024 |
| FY2022 | Dec 31, 2020 | $4.47B | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $4.43B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $4.47B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $4.53B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $4.46B | Feb 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.11B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $10.01B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $9.49B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $8.97B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $8.56B | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $8.08B | Feb 14, 2024 |
| FY2022 | Dec 31, 2019 | $7.97B | Feb 15, 2023 |
| FY2021 | Dec 31, 2018 | $7.57B | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $6.80B | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | $5.72B | Feb 26, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $566.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $837.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $548.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $493.00M | Feb 14, 2024 |
| FY2022 | Dec 31, 2021 | $459.00M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $564.00M | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $204.00M | Feb 25, 2022 |
| FY2021 | Dec 31, 2018 | $226.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $191.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | $181.00M | Feb 26, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $4.25B | Feb 28, 2014 |
| FY2012 | Dec 31, 2012 | $4.78B | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $1.60B | Feb 28, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | 2 | Feb 25, 2022 |
| FY2021 | Sep 30, 2021 | 2 | Feb 25, 2022 |
| FY2021 | Jun 30, 2021 | (1) | Feb 25, 2022 |
| FY2021 | Mar 31, 2021 | 2 | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 25, 2022 |
| FY2021 | Sep 30, 2020 | 1 | Feb 25, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 6 | Feb 14, 2025 |
| FY2021 | Dec 31, 2021 | 2 | Feb 25, 2022 |
| FY2021 | Sep 30, 2021 | 2 | Feb 25, 2022 |
| FY2021 | Jun 30, 2021 | (1) | Feb 25, 2022 |
| FY2021 | Mar 31, 2021 | 1 | Feb 25, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 25, 2022 |
| FY2021 | Sep 30, 2020 | 1 | Feb 25, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 223.94M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 223.59M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 222.76M | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | 222.35M | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | 221.81M | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | 220.64M | Feb 14, 2024 |
| FY2022 | Dec 31, 2019 | 219.64M | Feb 15, 2023 |
| FY2021 | Dec 31, 2018 | 219.14M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | 218.37M | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | 217.71M | Feb 26, 2020 |